Molecular Templates, Inc.

24 articles with Molecular Templates, Inc.

• 

  Top 10 Cities in the U.S. for the Job Market

  1/15/2019

  New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.
• 

  Molecular Templates and Takeda to Take on Multiple Myeloma in Deal Worth up to $632 Million

  9/20/2018

  Shares of Molecular Templates are up more than 52 percent in premarket trading after the company announced it has struck a deal with pharma giant Takeda Pharmaceuticals.

• Molecular Templates Provides Corporate Update and Outlines 2018 Milestones

  1/5/2018

  A look at the past year and what's in store for Molecular Templates in 2018.

• Molecular Templates Strengthens Management Team with Appointment of Adam Cutler as Chief Financial Officer

  11/15/2017

  Mr. Cutler will report to the CEO and will be responsible for all corporate finance, accounting, and investor relations activities.

• Molecular Templates Announces Dosing of First Patient in Phase 1 Expansion Study of MT-3724 in Diffuse Large B-Cell Lymphoma (DLBCL)

  10/24/2017

• Molecular Templates To Ring NASDAQ Closing Bell Friday, September 1, 2017

  8/30/2017

• Takeda And Molecular Templates Announce Multi-Target Research And Licensing Collaboration To Develop Next-Generation Oncology Therapies

  8/3/2017

• Molecular Templates Completes Merger With Threshold And Private Placements

  8/2/2017

• Crippled Bay Area Pharma Threshold Rockets on Reverse Merger Deal With Molecular Templates

  3/20/2017

• Molecular Templates Inc. To Present Clinical And Preclinical Data For MT-3724 And Next Generation Engineered Toxin Bodies (ETBS) At The 2016 AACR Annual Meeting

  4/6/2016

• Molecular Templates Inc. Presents Preclinical Data On De-Immunized Engineered Toxin Bodies (ETB) With Novel Immuno-Oncology Capabilities At The 2015 American Association for Cancer Research Annual Meeting

  4/16/2015

• Molecular Templates Inc. Announces Start Of Phase 1 Clinical Trial Of MT-3724 In Refractory Non-Hodgkin’s Lymphoma

  3/5/2015

• Veristat, Inc. And Molecular Templates Inc. Enter Into Preferred Provider Agreement For Refractory Non-Hodgkin’s B-Cell Lymphoma trial

  10/13/2014

• Molecular Templates Inc. Presents Preclinical Data On CD38-Targeted Engineered Toxin Body (ETB) At The American Association For Cancer Research Special Conference, Hematologic Malignancies: Translating Discoveries To Novel Therapies

  9/25/2014

• Molecular Templates Inc. Announces Completion Of $12 Million Series C Financing

  9/15/2014

• Molecular Templates Inc. Templates Announces FDA Approval Of Investigational New Drug Application For CD20 Internalizing Immunotoxin MT-3724

  9/8/2014

• Molecular Templates Inc. Presents Preclinical Data On Engineered Toxin Bodies (ETBs) At The American Association for Cancer Research Annual Meeting

  4/18/2014

• Molecular Templates Inc. Announces $8.5 Million Series C Financing and $10.6 Million Grant Funding

  10/8/2013

• Molecular Templates Inc. to Present at 2013 Biotechnology Industry Organization (BIO) International Convention

  4/22/2013

• Molecular Templates Inc. Announces RNAi Drug-Delivery Research Collaboration with Alnylam Pharmaceuticals

  5/4/2011